

**AMENDMENT**

**IN THE CLAIMS**

Please amend claims 1, 9, 11, and 19, as follows and shown in the attached Clean Set of Claims and Marked Up Version to Show Amendments:

1. [Twice Amended] An in vitro immunoassay method for diagnosing human colonic type gastric intestinal metaplasia which comprises the steps of:

- (a) contacting a gastric tissue sample of a subject suspected of having human colonic type gastric intestinal metaplasia cells with the monoclonal antibody DAS-1, or a fragment thereof, which monoclonal antibody is produced by the hybridoma deposited under ATCC accession number HB 9397 and which reacts with human gastric intestinal metaplasia antigen, wherein the gastric tissue is not a gastric cardia; and
- (b) detecting immunoreactivity between the gastric tissue and the monoclonal antibody, such immunoreactivity indicating a positive diagnosis of human colonic type gastric intestinal metaplasia.

9. [Twice Amended] The method according to claim 1, further comprising the step of performing a negative control assay on a negative control sample to detect cells in the gastric tissue sample of the subject suspected of having human colonic type gastric intestinal metaplasia and comparing results of the gastric tissue sample with the results of the negative control sample, wherein the presence of human colonic type gastric intestinal metaplasia cells in the gastric tissue sample over the absence of human colonic type gastric intestinal metaplasia cells in the negative control sample indicates a positive diagnosis of human colonic type gastric intestinal metaplasia.

11. [Twice Amended] An in vitro immunoassay method for screening for human colonic type gastric intestinal metaplasia, wherein reactivity with DAS-1 is indicative of a predisposition for gastric carcinoma, which comprises the steps of:

- (a) contacting a gastric tissue sample of a subject suspected of having human colonic type gastric intestinal metaplasia cells with the monoclonal antibody DAS-1, or a fragment thereof, which monoclonal antibody is produced by the hybridoma deposited under ATCC accession number HB 9397 and which reacts with human gastric intestinal metaplasia antigen, wherein the gastric tissue is not a gastric cardia; and
- (b) detecting immunoreactivity between the gastric tissue and the monoclonal antibody, such immunoreactivity indicating a positive diagnosis of human colonic type gastric intestinal metaplasia.

19. [Twice Amended]      The method according to claim 16, further comprising the step of performing a negative control assay on a negative control sample to detect cells in the gastric tissue sample of the subject suspected of having human colonic type gastric intestinal metaplasia and comparing results of the gastric tissue sample with the results of the negative control sample, wherein the presence of human colonic type gastric intestinal metaplasia cells in the gastric tissue sample over the absence of human colonic type gastric intestinal metaplasia cells in the negative control sample indicates a positive diagnosis of human colonic type gastric intestinal metaplasia..